Evaluation of moderate daily intake of beer in reducing menopausal symptoms: estrogenic effect of hop prenylflavanoids

ISRCTN ISRCTN14959650
DOI https://doi.org/10.1186/ISRCTN14959650
Secondary identifying numbers IRB00003099
Submission date
13/11/2017
Registration date
23/01/2018
Last edited
24/02/2023
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
The menopause is a natural part of ageing that usually occurs between 45 and 55 years of age as a woman's estrogen levels decline, which triggers the uncomfortable symptoms of hot flushes, night sweats, sleep disturbances, and vaginal dryness. These symptoms can significantly affect the quality of life of menopausal women. Phytoestrogens are compounds naturally found in some vegetables which act like estrogen - the most popular ones are soy and flax-seed phytoestrogens. Hops used in beer brewing are a rich source of phytoestrogens, and moderate daily intake of beer may decrease menopausal symptoms. Therefore, this study aims to find out whether moderate daily intake of beer reduces menopausal discomforts.

Who can participate?
Postmenopausal women aged between 45 and 70

What does the study involve?
Participants are assigned to one of the three study groups according to their preference due to the complexity of the mid-term alcohol intake of the intervention. The first group drink water, the second group drink beer without alcohol, and the third group drink regular beer every day for 6 months. At the beginning and at the end of each intervention period a medical assessment is performed which includes the participant’s clinical history, dietary evaluation, body measurements, blood pressure, and the collection of blood and urine samples.

What are the possible benefits and risks of participating?
Daily intake of beer may improve menopausal symptoms. There are no risks of participating in this study.

Where is the study run from?
Hospital Clínic of Barcelona (IDIBAPS) (Spain)

When is the study starting and how long is it expected to run for?
January 2017 to January 2020

Who is funding the study?
European Research Advisory Board (ERAB): The European Foundation for Alcohol Research

Who is the main contact?
Dr Rosa M Lamuela-Raventos

Contact information

Dr Rosa María Lamuela-Raventós
Scientific

Av. Joan XXIII, 27-31
Barcelona
08028
Spain

ORCiD logoORCID ID 0000-0002-1287-4560

Study information

Study designMid-term (6 months) non-randomized parallel-group controlled open intervention trial
Primary study designInterventional
Secondary study designNon randomised study
Study setting(s)Hospital
Study typePrevention
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet
Scientific titleEffects of prenylflavonoids of beer and dealcoholised beer on menopausal symptoms and estrogens
Study acronymPOLYBHOR
Study objectivesCurrent study hypothesis as of 11/05/2021:
Due to its phytoestrogen content, moderate beer consumption reduces menopausal symptoms and changes menopausal-related hormonal profile.

Previous study hypothesis:
Due to its phytoestrogen content, moderate beer consumption reduces menopausal symptoms and improves menopausal-related hormones.
Ethics approval(s)Institutional Review Board of the University of Barcelona, 09/03/2017
Health condition(s) or problem(s) studiedMenopause
InterventionCurrent interventions as of 11/05/2021:
All participants in the study are clinically examined and sign an informed consent to accept their participation in the study. Participants were assigned to one of the three study groups according to their preference due to the complexity of the mid-term alcohol intake of the intervention.

Intervention 1: control group with water for 6 months (ERB-C)
Intervention 2: 660 mL/day of dealcoholised beer for 6 months (ERB-D)
Intervention 3: 330 mL/day (15 g of ethanol/day) of regular beer for 6 months (ERB-A)

At the beginning and at the end of each intervention period a medical assessment will be performed which included: clinical history, dietary evaluation, anthropometric measurements, clinical blood pressure and full blood analysis (glucose, glycated hemoglobin, triglycerides, total cholesterol, HDLc, LDLc, lipoprotein (a), creatinine, calcium, phosphatase, PTH, 25OHD) and the collection of 24-h urine samples.


Previous interventions:
All participants in the study are clinically examined and sign an informed consent to accept their participation in the study. Participants are randomly assigned following simple randomisation procedures (computerised random numbers) to 1 of 3 intervention groups.

Intervention 1: control group with water for 6 months (ERB-C)
Intervention 2: 660 ml/day of dealcoholised beer for 6 months (ERB-D)
Intervention 3: 330 ml/day (15 g of ethanol/day) of regular beer for 6 months (ERB-A)

At the beginning, 6 months, 1 year and at the end of each intervention period a medical assessment will be performed which included: clinical history, dietary evaluation, anthropometric measurements, clinical blood pressure and full blood analysis (glucose, glycated hemoglobin, triglycerides, total cholesterol, HDLc, LDLc, lipoprotein (a), creatinine, calcium, phosphatase, PTH, 25OHD) and the collection of 24-h urine samples.
Intervention typeOther
Primary outcome measure1. Menopausal symptoms (hot flashes, sweating, palpitations, dizziness, vaginal dryness, mood swings, etc), measured using the Menopause Rating Scale at baseline, 1.5, 3 and 6 months
2. Calcium excretion, measured using liquid chromatography coupled mass spectrometry at baseline and 6 months
3. Menopausal-related hormone profile, measured using ELISA at baseline, 1.5, 3 and 6 months
Secondary outcome measuresCurrent secondary outcome measures as of 11/05/2021:
1. Dietary evaluation: nutrient intake and adherence to the dietary recommendations measured using a 7-day food record validated nutritional questionnaire at the baseline and at 6 months. In addition, the food frequency questionnaire and 14-point Mediterranean Diet Adherence questionnaire are recorded at baseline.
2. Physical activity is measured using the Minnesota Leisure Time Physical Activity questionnaire at baseline and 6 months
3. Bioavailability, identification and quantification of polyphenols in biological samples is measured using LTQ-Orbitrap Mass Spectrometry and HPLC-MS/MS at baseline and at the end of the intervention period
4. Changes in urine metabolites are measured using mass spectrometry and statistical analysis at baseline and at the end of the intervention period

Previous secondary outcome measures:
1. Dietary evaluation: nutrient intake and adherence to the dietary recommendations are measured using a 7-day food record validated nutritional questionnaire and a Food Frequency Test at the baseline, 6 months, 1 year and 2 years
2. Physical activity is measured using the Minnesota Leisure Time Physical Activity questionnaire at baseline, 6 months, 1 year and 2 years
3. Bioavailability, identification and quantification of polyphenols in biological samples is measured using LTQ-Orbitrap Mass Spectrometry and HPLC-MS/MS at baseline and at the end of the intervention period
4. Changes in urine metabolites are measured using mass spectrometry and statistical analysis at baseline and at the end of the intervention period
Overall study start date02/01/2017
Completion date30/01/2020

Eligibility

Participant type(s)Healthy volunteer
Age groupAdult
SexFemale
Target number of participants60
Total final enrolment37
Key inclusion criteriaCurrent inclusion criteria as of 11/05/2021:
Postmenopausal women between 45 and 70 years of age:
1. FSH 23-116 U/L
2. Estradiol (E2) <37 pg/ml
3. Amenorrhea ≥12 months

Previous inclusion criteria:
Women between 45 and 70 years of age within 5 years of menopause:
1. FSH >3 Miu/ml
2. Estradiol (E2) =30 pg/ml
3. Amenorrhea ≥12 months
Key exclusion criteriaCurrent exclusion criteria as of 28/05/2021:
1. Participants using estrogen therapy
2. Participants who received silicon or polyphenol supplements

Previous exclusion criteria:
1. Patients with known diseases affecting bone metabolism (rheumatoid arthritis, hyperthyroidism, surgical menopause, hypercortisolism, renal bone disease, chronic liver disease, among others)
2. Use of drugs affecting bone metabolism (fluorides, bisphosphonates, calcitonin, teriparatide or parathormone, strontium ranelate, SERMs, estrogen therapy, anabolic steroids, chronic glucocorticoids (> 3 months), cytostatics, antiandrogens and antiepileptics)
3. Participants who received silicon or polyphenol supplements
Date of first enrolment01/04/2017
Date of final enrolment30/06/2019

Locations

Countries of recruitment

  • Spain

Study participating centre

Hospital Clínic of Barcelona (IDIBAPS)
Villaroel 170
Barcelona
08036
Spain

Sponsor information

CIBER (Consorcio Centro de Investigación Biomédica en Red, M.P.)
Research organisation

C/Monforte de Lemos, 3-5. Pabellón 11. Planta 0
Madrid
28029
Spain

Website http://www.ciberobn.es
ROR logo "ROR" https://ror.org/00dwgct76

Funders

Funder type

Research organisation

European Research Advisory Board (ERAB): The European Foundation for Alcohol Research

No information available

Results and Publications

Intention to publish date01/06/2021
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planCurrent publication and dissemination plan, as of 14/12/2021:
During the recruitment period, the trialists have written a review about polyphenols and menopausal symptoms, “Beer polyphenols and menopause: effects and mechanisms – A review of current knowledge” (Oxidative Medicine and Cellular Longevity, 2017). After this period, they have published a second publication titled "Moderate consumption of beer (with and without ethanol) and menopausal symptoms: results from a parallel clinical trial in postmenopausal women" (Nutrients, 2021) https://doi.org/10.3390/nu13072278

Previous publication and dissemination plan as of 11/05/2021:
During the recruitment period, the trialists have written a review about polyphenols and menopausal symptoms, “Beer polyphenols and menopause: effects and mechanisms – A review of current knowledge” (Oxidative Medicine and Cellular Longevity, 2017). After this period, they plan to publish a second publication in a high-impact Journal about "Moderate daily beer (with and without ethanol) consumption and menopausal symptoms: results from a parallel clinical trial in postmenopausal women". It would be submitted by June 2021.

Previous publication and dissemination plan:
During the recruitment period, the trialists have written a review about polyphenols and menopausal symptoms, “Beer polyphenols and menopause: effects and mechanisms – A review of current knowledge” (Oxidative Medicine and Cellular Longevity, 2017). After this period, they plan to publish a second publication in a high-impact Journal about “Moderate beer consumption and menopausal symptoms: results from a randomized clinical trial in postmenopausal women”. It would be submitted by June 2018.
IPD sharing planThe datasets generated during and/or analysed during the current study are/will be available upon request from Dr Rosa M. Lamuela Raventós.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article 30/06/2021 24/02/2023 Yes No

Editorial Notes

24/02/2023: Publication reference added.
14/12/2021: The following changes were made to the trial record:
1. Publication reference added.
2. The publication and dissemination plan, was updated.
28/05/2021: The exclusion criteria were updated.
11/05/2021: The following changes were made to the trial record:
1. The study hypothesis, interventions, secondary outcome measures, inclusion criteria, plain English summary and publication and dissemination plan were updated.
2. The study design was changed from 'Mid-term (6 months) randomised parallel-group controlled open intervention trial' to 'Mid-term (6 months) non-randomized parallel-group controlled open intervention trial'.
3. The recruitment end date was changed from 31/12/2017 to 30/06/2019.
4. The overall trial end date was changed from 30/06/2018 to 30/01/2020.
5. The intention to publish date was changed from 01/06/2018 to 01/06/2021.
6. The total final enrolment number was added.